DERMATOMICS: Identifying Regulators of Skin Homeostasis

Launched by RELATION THERAPEUTICS · Mar 18, 2025

Keywords

ClinConnect Summary

The DERMATOMICS clinical trial is studying systemic sclerosis (SSc), a rare autoimmune condition that affects the skin and can cause serious complications in other organs. The goal of this research is to better understand how SSc develops and to identify new treatment options tailored to individual patients. By analyzing skin samples from participants, the researchers hope to uncover the hidden connections between genetics, skin structure, and environmental factors that influence this disease.

To participate in this study, individuals must be 18 years or older with a confirmed diagnosis of systemic sclerosis. The trial will also include healthy participants of a similar age and sex for comparison. Those interested in joining can expect to undergo a skin biopsy, which is a small procedure to collect a sample of skin for analysis. This research is important because it aims to find more effective treatments for SSc and other related skin and lung diseases, ultimately improving the quality of life for those affected.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• SSc participant cohort:
• • 1. Age of 18 years inclusive, or older at the time of signing the informed consent
• • 2. Documented diagnosis of systemic scleroderma (SSc) (early or late diagnosis)
• Healthy cohort:
• • 1. Approximate age/sex matching (majority of healthy participants to be recruited after cohort 1 and 2)
• • 2. Absence of Raynaud's Phenomenon
• • 3. Absence of lung disease
• • 4. Not on immunosuppressive treatment
• Exclusion Criteria:
• SSc participant cohort:
• • 1. Participants unable to provide informed consent.
• • 2. Participants with suspected/established underlying malignancy.
• • 3. Participants with suspected/established skin cancer.
• • 4. Participants with suspected/established bloodborne disease.
• • 5. Current enrolment or past participation in a study involving an investigational drug within 3 months or 5 half-lives of the investigational drug treatment (whichever is longer) before the day of sample collection.
• • 6. Participants treated with cellular therapies, e.g., HSCT, Car-T cells, T cell engagers.
• • 7. Participants treated with B-cell depletion therapies within 6 months.
• • 8. Concurrent diagnosis of any other connective tissue disease (CTD) in overlap.
• • 9. Diagnosis of other non-SSc dermatological conditions.
• • 10. Systemic sclerosis-like illness, including but not limited to localised scleroderma (morphoea), eosinophilic fasciitis, sclerodermoid graft-versus-host disease, fibro mucinous conditions (scleredema, scleromyxedema), scleroderma-like conditions that are associated with environmental chemical and drug exposure (e.g., toxic rapeseed oil, vinyl chloride, bleomycin, gadolinium-based contrast agents \[nephrogenic systemic fibrosis\], or due to metabolic disease).
• • 11. History or presence of significant non-sclereoderma related cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematologic, neurological disorders, or treatments for those, capable of significantly interfering with the results and interpretation of data.
• • 12. Smoking history (5 years smoke free acceptable)